21.4 C
New York
Sunday, September 25, 2022

H.C. Wainwright Stick to Their Buy Rating for ATAI Life Sciences By Investing.com

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on ATAI Life Sciences on Monday, setting a price target of $50, which is approximately 329.18% above the present share price of $11.65.

Trucchio expects ATAI Life Sciences to post earnings per share (EPS) of -$0.21 for the fourth quarter of 2021.

The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in ATAI Life Sciences, with an average price target of $31.33.
The analysts price targets range from a high of $50 to a low of $17.

In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $266 thousand and a net profit of -$33.36 million. The company’s market cap is $1.87 billion.

According to TipRanks.com, H.C. Wainwright analyst Patrick Trucchio is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.9% and a 33.33% success rate.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link

Related Articles

Stay Connected


Latest Articles